Thus, in addition to modulating the interaction between A2AR and D2R for PD treatment, our study suggests that A2AR ligands could also modulate GPCR-secretase interaction to regulate secretase activity for substrate processing, which may provide a novel target for AD. This evidence concerns the gene ADORA2A and Parkinson disease.